Gain Therapeutics, Inc.

NASDAQ:GANX

Biotechnology

Healthcare
$1.18 +3.09%

+$0.06 today

Market cap
$50.33M
Beta
0.16
P/E (TTM)
-3.6
EPS (TTM)
-$0.50
52W Low $1.41High $4.34

Volume 4.26M

Average 0.64M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$18.71M

FY 2025 · Annual

Net Income

-$20.16M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue164.99K140.11K55.18K00
Cost of Revenue00000
Gross Profit164.99K140.11K55.18K00
Gross Margin100.0%100.0%100.0%——
Research & Development7.16M8.38M11.52M10.79M10.21M
Selling, General & Admin6.83M9.54M10.79M9.56M8.5M
Operating Expenses13.99M17.92M22.31M20.35M18.71M
Depreciation & Amortization15.48K64.17K83.58K84.07K94.05K
EBITDA(13.87M)(17.43M)(22.1M)(19.79M)(19.21M)
EBITDA Margin-8407.0%-12443.0%-40059.2%——
Operating Income(13.83M)(17.78M)(22.25M)(20.35M)(18.71M)
Operating Margin-8379.8%-12688.1%-40328.3%——
Interest Income12.5K375.36K494.23K357.1K244.39K
Interest Expense00000
Other Income / Expenses(60.43K)279.28K64.89K476.22K(589.28K)
Income Before Tax(13.89M)(17.5M)(22.19M)(19.87M)(19.3M)
Pre-Tax Margin-8416.4%-12488.8%-40210.7%——
Income Tax Expense4.01K92.98K79.28K536.82K861.12K
Net Income(13.89M)(17.59M)(22.27M)(20.41M)(20.16M)
Net Margin-8418.9%-12555.1%-40354.3%——
EPS (Basic)(1.37)(1.48)(1.71)(0.89)(0.61)
EPS (Diluted)(1.37)(1.48)(1.71)(0.89)(0.61)
Weighted Avg Shares10.17M11.88M13.01M22.88M32.97M
Weighted Avg Shares (Diluted)10.17M11.88M13.01M22.88M32.97M

GANX Earnings Waterfall · TTM

NASDAQ:GANX · Revenue to Net Income

Key Ratios

EPS$-0.58
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.7
P/S Ratio0.0

Analysis

$0 of revenue converted into -$21.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.58, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 17, 2026
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
3Initial statement of beneficial ownershipOct 30, 2026

How much revenue does GANX generate?

Gain Therapeutics, Inc. (GANX) reported $0.00 of revenue in fiscal 2025.

Is GANX profitable?

Gain Therapeutics, Inc. (GANX) reported -$20.16M of net income.